Table 2.

Characteristics at time of AMPC diagnosis.

A. De Novo AMPC
Age at Diagnosis- yr: Median(Range)	56 (54–75)
Gleason score- no. (%)
7	1 (20)
9	1 (20)
10	1 (20)
Unknown	2 (40)
Sites of metastasis
None	3 (60)
Lymph Node Only	1 (20)
Visceral Metastases	1 (20)
B. Treatment-Emergent AMPC
PSA, median (range)	33.33 (0.61–3660)
Sites of Metastasis
Bone +/− Lymph Node	2
Visceral +/− Bone +/− Lymph Node	6
Time since initiation of ADT, months	41.1 (95% CI: 11.1–71.4)
Prior Treatments
ADT	7 (100)
Abiraterone	4 (57)
Enzalutamide	4 (57)
Docetaxel	5 (71)
Cabazitaxel	1 (14)
Docetaxel/Carboplatin	1 (14)
Radium-223	1 (14)
Sipuleucel-T	3 (43)